DekaBank Deutsche Girozentrale’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-100,000
| Closed | -$308K | – | 1430 |
|
|
2025
Q1 | $308K | Hold |
100,000
| – | – | ﹤0.01% | 1048 |
|
|
2024
Q4 | $913K | Hold |
100,000
| – | – | ﹤0.01% | 891 |
|
|
2024
Q3 | $284K | Hold |
100,000
| – | – | ﹤0.01% | 1106 |
|
|
2024
Q2 | $266K | Hold |
100,000
| – | – | ﹤0.01% | 1107 |
|
|
2024
Q1 | $302K | Hold |
100,000
| – | – | ﹤0.01% | 1085 |
|
|
2023
Q4 | $342K | Hold |
100,000
| – | – | ﹤0.01% | 1110 |
|
|
2023
Q3 | $241K | Hold |
100,000
| – | – | ﹤0.01% | 1157 |
|
|
2023
Q2 | $164K | Buy |
100,000
+20,000
| +25% | +$51.1K | ﹤0.01% | 1184 |
|
|
2023
Q1 | $245K | Hold |
80,000
| – | – | ﹤0.01% | 1156 |
|
|
2022
Q4 | $412K | Hold |
80,000
| – | – | ﹤0.01% | 1076 |
|
|
2022
Q3 | $255K | Buy |
+80,000
| New | +$265K | ﹤0.01% | 1182 |
|
|
2021
Q4 | – | Sell |
-22,000
| Closed | -$154K | – | 1495 |
|
|
2021
Q3 | $154K | Hold |
22,000
| – | – | ﹤0.01% | 1250 |
|
|
2021
Q2 | $213K | Hold |
22,000
| – | – | ﹤0.01% | 1205 |
|
|
2021
Q1 | $193K | Hold |
22,000
| – | – | ﹤0.01% | 1189 |
|
|
2020
Q4 | $249K | Buy |
+22,000
| New | +$232K | ﹤0.01% | 1146 |
|
DekaBank Deutsche Girozentrale's PSTX Position: Q2 2025 in Review
DekaBank Deutsche Girozentrale sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2025, closing a stake of 100,000 shares — an estimated $308K sold.
DekaBank Deutsche Girozentrale first reported a position in PSTX in Q4 2020 and held it in 15 quarters. The position peaked at $913K in Q4 2024. 0 funds tracked by Wall St. Rank hold PSTX as of Q2 2025.
- DekaBank Deutsche Girozentrale reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- DekaBank Deutsche Girozentrale sold 100,000 Poseida Therapeutics, Inc. Common Stock shares in Q2 2025, an estimated $308K.
- DekaBank Deutsche Girozentrale first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
- DekaBank Deutsche Girozentrale's Poseida Therapeutics, Inc. Common Stock position peaked at $913K in Q4 2024.
- 0 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2025.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2025, filed 30 Jul 2025.